PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

NCT06842472 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Ursodeoxycholic Acid (URSO)
RADIATION: Radiotherapy
DRUG: Adebrelimab (PD-L1 inhibitor)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences